Table 1 Detailed inclusion and exclusion criteria regarding the type of study, age, intervention and outcomes
Criteria | Inclusion | Exclusion | ||
|---|---|---|---|---|
Type of study | SR &MA | RCT | OS | editorials, opinion papers, case reports, case series, narrative reviews, letters, qualitative studies and observational studies which do not provide information of interest regarding adverse events |
Age of participants | mean or median age ≥ 65 years, or subgroup analysis ≥ 65 years | ≥ 80% of participants ≥ 65 years or a subgroup analysis ≥ 65 years | ||
Type of intervention | efficacy and/or safety of PAI as monotherapy or in combination with any other drug for the treatment or prevention of cerebral infarction, transient ischaemic attacks, peripheral artery occlusive disease and coronary disease or one of these indications versus placebo, no treatment, other drugs or a non-pharmacological intervention | focus on acute conditions (like exclusively acute treatment of myocardial infarction during the first hours) | ||
Clinically relevant outcomes | quality of life, mortality, life expectancy, hospitalization, cognitive impairment or cognitive status, functional impairment or functional status, cardiovascular event including stroke, renal failure, composite end points including any of the above (extraction of individual outcomes will be done if reported by original studies), adverse drug event, bleeding | surrogate endpoints (like laboratory measurements or blood pressure) | ||